The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer's disease patients and App^NL-F/NL-F mice.

"Declarations Ethics approval and consent to participateInformed consent for using brain and eye tissue, as well as clinical data for research purposes, was obtained from the patients or from their closest relatives, in accordance with the International Declaration of Helsinki and the Code of Conduct for Brain Banking. The tissue collection protocols were approved by the medical ethics committee of VU Amsterdam, and the Swedish Ethical Review Authority approved the study. All data were analyzed anonymously. Animal experiments were carried out in accordance with Swedish animal research regulations, and they were approved by the committee of animal research at Lund University (7482/2017). Consent for publicationNot applicable. Competing interestsM.W. has acquired research support (for the institution) from Eli Lilly. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. Competing interests M.W. has acquired research support (for the institution) from Eli Lilly. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens."

"Funding Open access funding provided by Lund University. This research was funded by the Swedish Research Council, Brain Foundation, Ögonfonden, Olle Engkvists Foundation, Dementia Foundation, Greta and Johan Kockska Foundation, and the Åhlén Foundation. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens."